1
|
Patil MN, Datkhile KD, Gudur AK, Gudur RA, Patil SR. Single-nucleotide polymorphism in CYP1A1, CYP1B1, CYP2B6, CYP2C8, and CYP2C9 genes and their association with gastrointestinal cancer: A hospital-based case-control study. J Cancer Res Ther 2024; 20:216-223. [PMID: 38554324 DOI: 10.4103/jcrt.jcrt_294_22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Accepted: 09/17/2022] [Indexed: 04/01/2024]
Abstract
BACKGROUND Cytochrome P450 (CYP) comprises a group of phase-I metabolizing enzymes that are important in xenobiotics metabolism. Genetic polymorphism of CYPs has been comprehensively studied for their association with a range of diseases. In this study, we assessed single-nucleotide polymorphism (SNP) of CYP1A, CYP1B, CYP2B, and CYP2C and their role in gastrointestinal (GI) cancer susceptibility in the rural population of Maharashtra. MATERIALS AND METHODS In this hospital-based case-control study, the association of polymorphism of CYP genes was studied by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The study subjects included 200 clinically confirmed GI cancer patients and equal number of healthy controls. Odds ratio (OR) with 95% confidence interval (CI) and P value were evaluated to find out the level of association, where P ≤ 0.005 was considered statistically significant. RESULTS After the analysis of CYP1A1*2A (rs4646903), CYP1B1*3 (rs1059836), CYP2B6*5 (rs3211371), CYP2C8*2 (rs11572103), CYP2C9*2 (rs1799853), and CYP2C9*3 (rs1057910), we noticed that variant (T) allele of CYP2B6*5 possessed significantly elevated risk (OR = 4.43; 95% CI: 2.20-8.90; P < 0.0001) of GI cancer in studied population. The genotypic distribution of G/C heterozygote allele of CYP1B1*3 (OR = 0.19, 95% CI = 0.12-0.32; P < 0.0001) and homozygous variant C/C allele (OR = 0.24, 95% CI = 0.13-0.45; P < 0.0001) showed a negative association with the development of GI cancer. CONCLUSION The findings from this study supported that polymorphism of CYP2B6*5gene may be involved in the development of GI cancer. However, other SNPs of CYP1A, CYP1B, and CYP2C genes did not signify the risk for GI cancer in the studied population of rural Maharashtra.
Collapse
Affiliation(s)
- Madhavi N Patil
- Department of Molecular Biology and Genetics, Krishna Institute of Medical Sciences "Deemed to be University", Satara, Maharashtra, India
| | - Kailas D Datkhile
- Department of Molecular Biology and Genetics, Krishna Institute of Medical Sciences "Deemed to be University", Satara, Maharashtra, India
| | - Anand K Gudur
- Department of Oncology, Krishna Institute of Medical Sciences "Deemed to be University", Satara, Maharashtra, India
| | - Rashmi A Gudur
- Department of Oncology, Krishna Institute of Medical Sciences "Deemed to be University", Satara, Maharashtra, India
| | - Satish R Patil
- Department of Molecular Biology and Genetics, Krishna Institute of Medical Sciences "Deemed to be University", Satara, Maharashtra, India
| |
Collapse
|
2
|
Datkhile KD, Patil SR, Patil MN, Durgawale PP, Jagdale NJ, Deshmukh VN, More AL, Gudur RA, Gudur AK. Genetic polymorphisms of CYP1A, CYP1B, CYP2C and risk of cervical cancer among rural population of Maharashtra: Findings from a hospital-based case-control study. J Cancer Res Ther 2023; 19:1925-1930. [PMID: 38376298 DOI: 10.4103/jcrt.jcrt_292_21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2021] [Accepted: 04/29/2022] [Indexed: 02/21/2024]
Abstract
BACKGROUND Last few decades, multiple studies all over the world revealed the association of genetic polymorphism in cytochrome P450 (CYP) genes with risk of developing different type of cancers, but contradictory outcomes were evidenced in case of cervical cancer (CC) risk. Therefore, the discrepancies in earlier reports influenced us to evaluate the association of CYP1A1*2A rs4646903, CYP1B1*3 rs1056836, CYP2C8*2 rs11572103, CYP2C9*2 rs1799853, CYP2C9*3 rs1057910, and CYP2C19*2 rs4244285 polymorphisms and CC susceptibility in the women of rural population of Maharashtra. MATERIALS AND METHODS In this case-control study, genetic association of the polymorphisms in CYP genes was studied by using polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) method. The study was conducted among 350 clinically confirmed CC patients and 350 healthy volunteers in a population of south-western Maharashtra. The odds ratio (OR) with 95% confidence interval (CI) and P value were evaluated to get the level of association where P ≤ 0.005 was considered as statistically significant. RESULTS After the analysis of single-nucleotide polymorphism (SNPs) of CYP1A1, CYP1B1, CYP2C8, CYP2C9, and CYP2C19, we noticed that CYP1B1*3 rs1056836 (Leu4326Val) polymorphism possessed a significantly elevated risk (OR = 3.28; 95% CI: 2.18-4.94; P < 0.0001), whereas CYP2C19*2 rs4244285 showed significantly lower risk (OR: 0.53, 95% CI: 0.33-0.85 P < 0.009) of CC in the studied rural population. CONCLUSION The findings from this study supported that rs1056836 SNP of CYP1B1*3 increase CC development, whereas rs4244285 of CYP2C19*2 lowers the CC risk in the studied population.
Collapse
Affiliation(s)
- Kailas D Datkhile
- Department of Molecular Biology and Genetics, Krishna Institute of Medical Sciences "Deemed to be University", Taluka-Karad, Dist- Satara, Maharashtra, India
| | - Satish R Patil
- Department of Molecular Biology and Genetics, Krishna Institute of Medical Sciences "Deemed to be University", Taluka-Karad, Dist- Satara, Maharashtra, India
| | - Madhavi N Patil
- Department of Molecular Biology and Genetics, Krishna Institute of Medical Sciences "Deemed to be University", Taluka-Karad, Dist- Satara, Maharashtra, India
| | - Pratik P Durgawale
- Department of Molecular Biology and Genetics, Krishna Institute of Medical Sciences "Deemed to be University", Taluka-Karad, Dist- Satara, Maharashtra, India
| | - Nilam J Jagdale
- Department of Molecular Biology and Genetics, Krishna Institute of Medical Sciences "Deemed to be University", Taluka-Karad, Dist- Satara, Maharashtra, India
| | - Vinit N Deshmukh
- Department of Molecular Biology and Genetics, Krishna Institute of Medical Sciences "Deemed to be University", Taluka-Karad, Dist- Satara, Maharashtra, India
| | - Ashwini L More
- Department of Molecular Biology and Genetics, Krishna Institute of Medical Sciences "Deemed to be University", Taluka-Karad, Dist- Satara, Maharashtra, India
| | - Rashmi A Gudur
- Department of Oncology, Krishna Institute of Medical Sciences "Deemed to be University", Taluka-Karad, Dist- Satara, Maharashtra, India
| | - Anand K Gudur
- Department of Oncology, Krishna Institute of Medical Sciences "Deemed to be University", Taluka-Karad, Dist- Satara, Maharashtra, India
| |
Collapse
|
3
|
Yadav VK, Katiyar T, Ruwali M, Yadav S, Singh S, Hadi R, Bhatt MLB, Parmar D. Polymorphism in cytochrome P4502A6 reduces the risk to head and neck cancer and modifies the treatment outcome. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS 2021; 62:502-511. [PMID: 34655463 DOI: 10.1002/em.22466] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/27/2021] [Revised: 09/26/2021] [Accepted: 10/11/2021] [Indexed: 06/13/2023]
Abstract
The present case-control study consisting of 1300 cases of head and neck squamous cell carcinoma (HNSCC) and the equal number of controls aimed to investigate the association of functionally important polymorphisms in cytochrome P4502A6 (CYP2A6*1B, CYP2A6*4C, CYP2A6*9-rs28399433) with HNSCC and the treatment response in cases receiving a combination of chemotherapy/radiotherapy (CT/RT). A significant decrease in risk to HNSCC was observed in the cases with deletion (CYP2A6*4B and CYP2A6*4C) or reduced activity genotypes (CYP2A6*9) of CYP2A6. This risk to HNSCC was further reduced significantly in tobacco users among the cases when compared to nontobacco users among the cases. The risk was also reduced to a slightly greater extent in alcohol users among the cases when compared to nonalcohol users among the cases. In contrast with decreased risk to HNSCC, almost half of the cases with variant genotypes of CYP2A6 (CYP2A6*1A/*4C+*1B/*4C+*4C/*4C and *9/*9) did not respond to the treatment. Likewise, the survival rate in cases receiving the treatment, after 55 months of follow-up was significantly lower in cases with deletion (6.3%) or reduced activity (11.9%) allele than in the cases with common alleles (41%). The present study has shown that CYP2A6 polymorphism significantly reduces the risk to HNSCC. Our data further suggested that CYP2A6 polymorphism may worsen the treatment outcome in the cases receiving CT/RT.
Collapse
Affiliation(s)
- Vinay Kumar Yadav
- System Toxicology and Health Risk Assessment Group, CSIR-Indian Institute of Toxicology Research, Lucknow, India
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India
| | - Tridiv Katiyar
- System Toxicology and Health Risk Assessment Group, CSIR-Indian Institute of Toxicology Research, Lucknow, India
| | - Munindra Ruwali
- Faculty of Science, Engineering And Technology, Amity University, Gurgaon, India
| | - Sanjay Yadav
- All India Institute of Medical Sciences, Raebareli, India
| | - Sudhir Singh
- Department of Radiotherapy, King George's Medical University, Lucknow, India
| | - Rahat Hadi
- Department of Radiation Oncology, Dr Ram Manohar Lohia Institute of Medical Sciences, Lucknow, India
| | | | - Devendra Parmar
- System Toxicology and Health Risk Assessment Group, CSIR-Indian Institute of Toxicology Research, Lucknow, India
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India
| |
Collapse
|
4
|
Long L, Pang XX, Zeng FM, Zhan XH, Xie YH, Pan F, Wang W, Liao LD, Xu XE, Li B, Wang LD, Chang ZJ, Li EM, Xu LY. Promotion of rs3746804 (p. L267P) polymorphism to intracellular SLC52A3a trafficking and riboflavin transportation in esophageal cancer cells. Amino Acids 2021; 53:1197-1209. [PMID: 34223992 DOI: 10.1007/s00726-021-03025-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2020] [Accepted: 06/21/2021] [Indexed: 02/05/2023]
Abstract
Riboflavin is an essential micronutrient for normal cellular growth and function. Lack of dietary riboflavin is associated with an increased risk for esophageal squamous cell carcinoma (ESCC). Previous studies have identified that the human riboflavin transporter SLC52A3a isoform (encoded by SLC52A3) plays a prominent role in esophageal cancer cell riboflavin transportation. Furthermore, SLC52A3 gene single nucleotide polymorphisms rs3746804 (T>C, L267P) and rs3746803 (C >T, T278M) are associated with ESCC risk. However, whether SLC52A3a (p.L267P) and (p.T278M) act in riboflavin transportation in esophageal cancer cell remains inconclusive. Here, we constructed the full-length SLC52A3a protein fused to green fluorescent protein (GFP-SLC52A3a-WT and mutants L267P, T278M, and L267P/T278M). It was confirmed by immunofluorescence-based confocal microscopy that SLC52A3a-WT, L267P, T278M, and L267P/T278M expressed in cell membrane, as well as in a variety of intracellular punctate structures. The live cell confocal imaging showed that SLC52A3a-L267P and L267P/T278M increased the intracellular trafficking of SLC52A3a in ESCC cells. Fluorescence recovery after photobleaching of GFP-tagged SLC52A3a meant that intracellular trafficking of SLC52A3a-L267P and L267P/T278M was rapid dynamics process, leading to its stronger ability to transport riboflavin. Taken together, the above results indicated that the rs3746804 (p.L267P) polymorphism promoted intracellular trafficking of SLC52A3a and riboflavin transportation in ESCC cells.
Collapse
Affiliation(s)
- Lin Long
- Institute of Oncologic Pathology, Department of Biochemistry and Molecular Biology, Shantou University Medical College, 22 Xinling Road, Shantou, 515041, Guangdong, China
| | - Xiao-Xiao Pang
- Institute of Oncologic Pathology, Department of Biochemistry and Molecular Biology, Shantou University Medical College, 22 Xinling Road, Shantou, 515041, Guangdong, China
- Department of Pathology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510000, Guangdong, China
| | - Fa-Min Zeng
- Institute of Oncologic Pathology, Department of Biochemistry and Molecular Biology, Shantou University Medical College, 22 Xinling Road, Shantou, 515041, Guangdong, China
| | - Xiu-Hui Zhan
- Research Center of Translational Medicine, Department of Spine Surgery, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
| | - Ying-Hua Xie
- Institute of Oncologic Pathology, Department of Biochemistry and Molecular Biology, Shantou University Medical College, 22 Xinling Road, Shantou, 515041, Guangdong, China
| | - Feng Pan
- Institute of Oncologic Pathology, Department of Biochemistry and Molecular Biology, Shantou University Medical College, 22 Xinling Road, Shantou, 515041, Guangdong, China
| | - Wei Wang
- Institute of Oncologic Pathology, Department of Biochemistry and Molecular Biology, Shantou University Medical College, 22 Xinling Road, Shantou, 515041, Guangdong, China
| | - Lian-Di Liao
- Institute of Oncologic Pathology, Department of Biochemistry and Molecular Biology, Shantou University Medical College, 22 Xinling Road, Shantou, 515041, Guangdong, China
| | - Xiu-E Xu
- Institute of Oncologic Pathology, Department of Biochemistry and Molecular Biology, Shantou University Medical College, 22 Xinling Road, Shantou, 515041, Guangdong, China
| | - Bin Li
- State Key Laboratory of Luminescence and Applications, Changchun Institute of Optics, Fine Mechanics and Physics, Chinese Academy of Science, Changchun, China
| | - Li-Dong Wang
- Henan Key Laboratory for Cancer Research, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Zhi-Jie Chang
- State Key Laboratory of Membrane Biology, School of Medicine, Tsinghua University, Beijing, China
| | - En-Min Li
- Institute of Oncologic Pathology, Department of Biochemistry and Molecular Biology, Shantou University Medical College, 22 Xinling Road, Shantou, 515041, Guangdong, China.
| | - Li-Yan Xu
- Institute of Oncologic Pathology, Department of Biochemistry and Molecular Biology, Shantou University Medical College, 22 Xinling Road, Shantou, 515041, Guangdong, China.
| |
Collapse
|
5
|
Ma J, Hu X, Dai B, Wang Q, Wang H. Bioinformatics analysis of laryngeal squamous cell carcinoma: seeking key candidate genes and pathways. PeerJ 2021; 9:e11259. [PMID: 33954053 PMCID: PMC8052978 DOI: 10.7717/peerj.11259] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2020] [Accepted: 03/22/2021] [Indexed: 12/20/2022] Open
Abstract
Background Laryngeal squamous cell carcinoma (LSCC) is the second most aggressive head and neck squamous cell carcinoma. Although much work has been done to optimize its treatment, patients with LSCC still have poor prognosis. Therefore, figuring out differentially expressed genes (DEGs) contained in the progression of LSCC and employing them as potential therapeutic targets or biomarkers for LSCC is extremely meaningful. Methods Overlapping DEGs were screened from two standalone Gene Expression Omnibus datasets, and Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were performed. By applying STRING and Cytoscape, a protein–protein network was built, and module analysis was carried out. The hub genes were selected by maximal clique centrality with the CytoHubba plugin of Cytoscape. UALCAN and GEPIA data were examined to validate the gene expression findings. Moreover, the connection of the hub genes with LSCC patient overall survival was studied employing The Cancer Genome Atlas. Then, western blot, qRT-PCR, CCK-8, wound healing and transwell assays were bring to use for further verify the key genes. Results A total of 235 DEGs were recorded, including 83 upregulated and 152 downregulated genes. A total of nine hub genes that displayed a high degree of connectivity were selected. UALCAN and GEPIA databases verified that these genes were highly expressed in LSCC tissues. High expression of the SPP1, SERPINE1 and Matrix metalloproteinases 1 (MMP1) genes was connected to worse prognosis in patients with LSCC, according to the GEPIA online tool. Western blot and qRT-PCR testify SPP1, SERPINE1 and MMP1 were upregulated in LSCC cells. Inhibition of SPP1, SERPINE1 and MMP1 suppressed cell proliferation, invasion and migration. Conclusion The work here identified effective and reliable diagnostic and prognostic molecular biomarkers by unified bioinformatics analysis and experimental verification, indicating novel and necessary therapeutic targets for LSCC.
Collapse
Affiliation(s)
- Jinhua Ma
- Department of Otolaryngology, Cangzhou Central Hospital, Cangzhou, Hebei, China
| | - Xiaodong Hu
- Department of Otolaryngology, Cangzhou Central Hospital, Cangzhou, Hebei, China
| | - Baoqiang Dai
- Department of Otolaryngology, Cangzhou Central Hospital, Cangzhou, Hebei, China
| | - Qiang Wang
- Department of Otolaryngology, Cangzhou Central Hospital, Cangzhou, Hebei, China
| | - Hongqin Wang
- Department of Otolaryngology, Cangzhou Central Hospital, Cangzhou, Hebei, China
| |
Collapse
|